Stock Alert: Moderna Down 5% After Losing Patent Dispute

(RTTNews) - Shares of Moderna Inc. (MRNA) slipped over 5% on Friday morning after the company lost a patent case related to a technology used in its Covid-19 vaccine.

MRNA is currently trading at $71.54, down $3.79 or 5.04%, on the Nasdaq.

Moderna had filed the patent case against Arbutus Biopharma (ABUS) in January last year. Moderna argued that Arbutus patent for lipid nanoparticles, the technology used to deliver messenger RNA to a patients' cells, was unpatentable.

However, the Patent Trial and Appeal Board ruled in favor of Arbutus. The coronavirus vaccine candidate mRNA-1653, being developed by Moderna, is based on the LNP technology.

Arbutus shares are currently trading up 25%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More